1Appelbaum FR. Haematopoietic cell transplantation as immunotherapy[J]. Nature, 2001,411:385-389.
2Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-versus-host disease alter bone marrow transplant [J].Annu Rex Med, 2003, 54: 29-52.
3Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class Ⅰ and Ⅱ alleles in the donor and recipient[J]. Blood, 1998, 92(10) :3515-3520.
4McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects[J]. Blood, 2001,97:3390-3400.
5Dahl AM, Beverley PC, Stauss HJ. A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein[J]. J Immu, 1996,157:239-246.
6Randolph SS, Gooley TA, Warren EH, et al. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants [J].Blood, 2004,103:347-352.
7Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants[J ]. Science, 2002, 295:2097-2100.
9Strair RK, Schaar D, Medina D, et al. Antineoplastic effects of partially HLA-matched irradiated blood mononuclear cells in patients with renal cell carcinoma[J] . J Clini Onco, 2003, 21:3785-3791.
10Moscovitch M, Slavin S. Antitumor effect of allogeneic bone marrow transplantation in (NZB x NZW) F1 hybrids with spontaneous lymphosarcoma[J]. J Immu, 1984,132:997-1003.
3Vivier E, Tomasello E, Paul P. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition. Curr Opin Immunol, 2002;14:306 -311
4Diefenbach A, Tomasello E, Lucas M, et al. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol, 2002; 3 : 1142 -1149
5Diefenbach A, Jensen ER, Jamieson AM, et al. Rael and H60 ligands of the NKG2D receptor stimulate tumour immunity.Nature, 2001 ;413 (6852) : 165 - 171
6Cerwenka A, Bakker AB, McClanahan T, et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity, 2000; 12:721 -727
7O' Callaghan CA, Cerwenka A, Willcox BE, et al. Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60. Immunity, 2001 ;15:201 -211
9Renga M, Pedrazzoli P, Siena S. Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors. Ann Oncol, 2003 ;14:1177 - 1184
10Storb RF, Lucarelli G, McSweeney PA, et al. Hematopoietic cell transplantation for benign hematological disorders and solid tumors.Hematology. Am Soc Hematol Educ Program, 2003:372 -397
